Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers.

Christoph KesselRichard VollenbergKatja MasjosthusmannClaas H HinzeHelmut WittkowskiFrance DebaugniesCarole NagantFrancis CorazzaFrédéric VélyGilles KaplanskiCharlotte Girard-Guyonvarc'hCem GabayHartmut SchmidtDirk Foell Phil-Robin Tepasse

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

Serum biomarker profiles clearly separate COVID-19 from MAS or secondary HLH in terms of distinguishing the severe systemic hyperinflammation that occurs following SARS-CoV-2 infection. These findings could be useful in determining the efficacy of drugs targeting key molecules and pathways specifically associated with systemic cytokine storm conditions in the treatment of COVID-19.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
drug induced
oxidative stress
diabetic rats
early onset
stress induced